Author(s): Zhang Y, GarciaBuitrago MT, KoruSengul T, Schuman S, GanjeiAzar P
Abstract Share this page
Abstract Serous papillary carcinomas (SPCs) share a similar morphology regardless of whether they originate from the ovary or the uterus. Identification of the site of origin of the tumor can be a challenging and a diagnostic dilemma, particularly, in the setting of a pelvic mass or peritoneal carcinomatosis. Recognition of the site of origin influences the staging, management, and prognosis of these malignancies. The purpose of this study is to identify a panel of markers to distinguish the ovarian serous papillary carcinomas (OSPC) from the uterine serous papillary carcinomas (USPC). Formalin-fixed, paraffin-embedded archival tissue from 46 cases of SPCs (33 uterine and 13 ovarian) were stained using antibodies for estrogen receptor (ER), WT1, insulin-like growth factor-II mRNA-binding protein 3 (IMP3), p53, and p16. The OSPC expressed ER (92\%), WT1 (100\%), IMP3 (92\%), p53 (92\%), and p16 (92\%). The USPCs expressed ER (30\%), WT1 (64\%), IMP3 (85\%), p53 (64\%), and p16 (76\%). Only ER expression was significantly higher in OSPC compared with USPCs (P<0.001). The combined ER(+)WT1(+) phenotype was present in 92\% of the OSPC, whereas only 18\% of the USPCs had the same phenotype (P<0.001). Furthermore, 71\% of the OSPCs expressed ER(+), p53(+), WT1(+), IMP3(+), and p16(+) immunophenotype, whereas in USPCs, the tumor cells showed immunophenotypic diversity, with only 6\% of the USPCs expressing reactivity to all the 5 markers (P<0.001). This study suggests that ER alone or in combination with a limited panel of markers may be used to identify the site of origin of SPCs.
This article was published in Int J Gynecol Pathol
and referenced in Journal of Addiction Research & Therapy